CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
Real-time Estimate Cboe BZX  -  05/16 03:06:03 pm EDT
25.49 USD   +6.65%
05/11Berenberg Bank Adjusts Cerevel Therapeutics Holdings Price Target to $44 From $46, Maintains Buy Rating
MT
05/10Cerevel Therapeutics Q1 Loss Widens
MT
05/10CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference

01/03/2022 | 07:01am EDT

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that Chairperson and Chief Executive Officer Tony Coles, M.D., will present at the upcoming virtual 40th Annual J.P. Morgan Healthcare Conference. Dr. Coles will be joined by Chief Medical Officer Raymond Sanchez, M.D., and Chief Scientific Officer John Renger, Ph.D., for the question-and-answer portion of the presentation.

Date: Monday, January 10, 2022

Format: Presentation at 2:15 p.m. ET

The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics website here. A replay will be available in the same section of the company’s website.

About Cerevel Therapeutics

Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising six clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia, and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or potential acquisitions. For more information, visit www.cerevel.com.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about our upcoming conference participation and the potential attributes and benefits of our product candidates. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: that we may not be able to realize the expected benefits of the collaboration; clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19 on the timing, progress and results of ongoing or planned clinical trials; other impacts of COVID-19, including operational disruptions or delays or to our ability to raise additional capital; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading “Risk Factors” in our Quarterly Report on Form 10-Q filed with the SEC on November 10, 2021 and our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:
Anna Robinson
Anna.robinson@cerevel.com

Investor Contact:
Matthew Calistri
Matthew.calistri@cerevel.com

 


Primary Logo

Source: Cerevel Therapeutics

2022 GlobeNewswire, Inc., source Press Releases

All news about CEREVEL THERAPEUTICS HOLDINGS, INC.
05/11Berenberg Bank Adjusts Cerevel Therapeutics Holdings Price Target to $44 From $46, Main..
MT
05/10Cerevel Therapeutics Q1 Loss Widens
MT
05/10CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial ..
AQ
05/10Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ende..
CI
05/10Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
AQ
04/18INSIDER SELL : Cerevel Therapeutics Holdings
MT
04/13Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update..
AQ
04/08SIRS 2022 PRESENTATION – EMRAC : Results From a Phase 1b Trial in Patients With Schi..
PU
04/06AAN 2022 POSTER - PHARMACOKINETICS, : Summary of Early Phase Clinical Studies
PU
04/06AAN 2022 PRESENTATION - DARIGABAT : pronounced antiepileptic activity in the mesial tempor..
PU
More news
Analyst Recommendations on CEREVEL THERAPEUTICS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -275 M - -
Net cash 2022 247 M - -
P/E ratio 2022 -12,7x
Yield 2022 -
Capitalization 3 544 M 3 544 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 228
Free-Float 81,4%
Chart CEREVEL THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Cerevel Therapeutics Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CEREVEL THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 23,90 $
Average target price 42,86 $
Spread / Average Target 79,3%
EPS Revisions
Managers and Directors
N. Anthony Coles Executive Chairman & Chief Executive Officer
Abraham N. Ceesay President
Mark Bodenrader VP-Finance, Chief Financial & Accounting Officer
John Renger Chief Scientific Officer
Raymond Sanchez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CEREVEL THERAPEUTICS HOLDINGS, INC.-26.28%3 544
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-14.92%43 023
BIONTECH SE-38.39%38 601